When was Angstrom founded?

Angstrom was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Angstrom located?

Angstrom is headquartered in Austin, United States.

How many employees does Angstrom have?

As of Jul 01, 2024, the latest employee count at Angstrom is 7.

Is Angstrom a funded company?

Angstrom is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jun 16, 2021.

When was the latest funding round of Angstrom?

Angstrom's latest funding was a $***** Series A round on Jun 16, 2021, with participation from 1 investor. Its primary sector is Infectious Diseases. In United States, the Infectious Diseases sector has seen $407M in funding in 2026 to date.

Where does Angstrom rank among its competitors?

Angstrom ranks 22nd amongst 85 active competitors, of which 22 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Rapidemic, which secured $2.7M in Sep, 2025.

Who are the top competitors of Angstrom?

Angstrom's top competitors include Souzhou Ribo Life Science, PathoQuest and Hememics Biotechnologies. Among them, Rapidemic secured the most recent funding round in September, 2025.

Angstrom - 2026 Company Profile, Team, Funding & Competitors

Angstrom is a series A company based in Austin (United States), founded in 2019 by David States. It operates as a Provider of high-frequency COVID-19 and respiratory pathogen testing platform. Angstrom has raised $3M in funding from GreyBird Ventures. The company has 85 active competitors, including 22 funded and 12 that have exited. Its top competitors include companies like Souzhou Ribo Life Science, PathoQuest and Hememics Biotechnologies.

Company Details

Provider of high-frequency COVID-19 and respiratory pathogen testing platform. The company has AMPD nanopore sequencing and a machine learning-powered platform. It is used for the diagnostics of covid-19, influenza, and respiratory pathogens.

Website: angstrom.bio
Email ID: *****@angstrom.bio

Key Metrics

Founded Year

2019

Location

Austin, United States

Stage

Series A

Total Funding

$3M in 1 round

Latest Funding Round

Series A, Jun 16, 2021, $*****

Investors

GreyBird Ventures

Ranked

22^nd among 85 active competitors

Employee Count

7 as on Jul 01, 2024

Similar Companies

Souzhou Ribo Life Science & 107 more

View Angstrom's full profile

Angstrom has raised a total funding of $3M over 1 round. Its latest funding round was a Series A round on Jun 16, 2021 for $*****. 1 investor participated in its latest round. Angstrom has 1 institutional investor.

Here is the list of recent funding rounds of Angstrom:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 16, 2021	7423171	Series A	2263551	9077791	2465938	2969568

Access funding benchmarks and valuations. Sign up today!

View details of Angstrom's funding rounds and investors

The founders of Angstrom is David States.

Here are the details of Angstrom's key team members:

David States: Co-Founder of Angstrom and founder of 1 other company.
Contact Info: 1 email address

View details of Angstrom's Founder profiles and Board Members

Angstrom's employee count trend

Angstrom has 7 employees as of Jul 24. Here is Angstrom's employee count trend over the years:

Uncover Angstrom's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Angstrom include Souzhou Ribo Life Science, PathoQuest and Hememics Biotechnologies. Here is the list of Top 10 competitors of Angstrom, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Souzhou Ribo Life Science 2007, Suzhou (China), Public	Developer of nucleic acid drugs based on RNA interference (RNAi) technology	$201M	Panlin Capital, SDIC Innovation & 13 others	59/100
2nd	PathoQuest 2010, Paris (France), Acquired	Provider of next-generation sequencing for microbiology testing	$9.99M	Kurma Partners, Charles River Laboratories ... & 8 others	57/100
3rd	Hememics Biotechnologies 2009, Gaithersburg (United States), Seed	Developer of techology platform for biopreservation	$4.6M	American Vietnamese Investment Partners, TEDCO ... & 2 others	55/100
4th	OraSure 1987, Bethlehem (United States), Public	Provider of point-of-care diagnostic devices for oral fluid specimens	-	Public Health Emergency, One Putt Ventures ... & 4 others	51/100
5th	Quantalife 2008, Pleasanton (United States), Acquired	Life science research and clinical diagnostics solutions provider, powering possibilities	$28.7M	Paladin Capital, VC23 & 3 others	46/100
6th	Daktari Diagnostics 2008, Boston (United States), Series D	Point of care diagnostic platform and data management system	$73.4M	Merck Global Health Innovation Fund, Eastern Capital ... & 10 others	45/100
7th	Senzo 2013, San Francisco (United States), Seed	Developer of point-of-care diagnostic device for the detection of infectious diseases	$9.6M	BioAdvance, Wellness Coaches & 4 others	45/100
8th	Rapidemic 2020, Leiden (Netherlands), Seed	Developer of diagnostic kits for infectious diseases	-	Graduate Ventures, Gates Foundation & 2 others	43/100
9th	Voxtur Bio 2013, Thane (India), Seed	Develops kits and reagents for in vitro diagnostics	$3.16M	Equity Intelligence, White Whale Partners ... & 47 others	43/100
10th	Bionxt 2018, Vancouver (Canada), Public	Developer of drug formulations and delivery systems for various diseases	-	Planet Ventures	43/100
22nd	Angstrom 2019, Austin (United States), Series A	Provider of high-frequency COVID-19 and respiratory pathogen testing platform	$3M	GreyBird Ventures	34/100